BPC-157: What Research Shows and What It Does Not

Bottom line

BPC-157 is a 15-amino-acid peptide originally isolated from gastric juice. [1] It is not an FDA-approved medicine, and its use is banned in professional sports. [2] Nearly all the supporting research is in animals. Evidence labels used here: preclinical (cells or animals only), insufficient evidence, no good evidence of benefit (in the sense that good human trials do not exist), marketing claim. This page is education only: no amounts, sources, or how-to-use details.

What it is

Reviews describe BPC-157 ("body protection compound-157") as a synthetic pentadecapeptide, meaning a chain of 15 amino acids, derived from a protein in gastric juice. [1] It is sold online and promoted for tendon, muscle, joint and gut healing.

Regulatory and sport status

• United States (FDA). The FDA's compounding page, current as of April 22, 2026, lists BPC-157 in a table of substances that were nominated for compounding and then withdrawn by the nominators. For it the FDA says compounded drugs may pose immune-reaction risk and peptide-impurity and ingredient-characterization problems, and that it "has identified no, or only limited, safety-related information" and so lacks enough information to know whether it would cause harm in humans. [3] A 2025 review states plainly that it lacks FDA approval. [2] We did not verify the status in the EU, UK, Canada or Australia.
• Sport (WADA). The World Anti-Doping Agency's Prohibited List names BPC-157 among non-approved substances prohibited at all times. [4] Athletes in tested sports should check their organization's rules.

What research shows

Animals. A 2019 review found studies reported consistently positive healing effects in tendon, ligament and muscle injury models, but mostly in small rodent studies from a handful of research groups, and said efficacy is yet to be confirmed in humans. [5] A 2025 systematic review included 36 studies, 35 preclinical and 1 clinical, and noted that animal models showed improved outcomes in muscle, tendon, ligament and bone injury. [2] Label: preclinical. Animal findings are not human findings.

Humans. Human evidence is very small:

• A 2026 systematic review found only three human studies (30 people in total): a retrospective knee-injection study, a retrospective bladder-instillation study for interstitial cystitis, and a small intravenous safety pilot. All were judged poor quality, with certainty of evidence rated very low. The authors concluded BPC-157 should not be used clinically in humans outside approved, high-quality trials. [6]


• The knee study was a retrospective chart review at one clinic, followed by phone surveys of 16 patients, without validated tools to measure function. [7] Such designs cannot show that the peptide, rather than time or placebo effect, caused improvement.


• A 2025 review likewise says only three pilot studies exist and that BPC-157 should be considered investigational. [1]

Label for human efficacy in any injury or condition: insufficient evidence. Proper evidence not found for large randomized trials; we checked PubMed-indexed systematic reviews through 2026.

Safety and unknowns

Reports of no adverse effects in the tiny human studies cannot establish safety. [6] A 2025 systematic review found no clinical safety data and warned of possible harms from unregulated manufacturing, contamination, or unknown clinical safety. [2] Because products are sold outside regulation, the actual contents and purity of a vial are unknown. Injected products carry infection and immune-reaction risks; see peptide safety and adverse events.

Special groups

No safety data exist for pregnancy, breastfeeding, children, older adults, or people with heart, liver, kidney or cancer histories; the FDA says it lacks information on human harm. [3] Proper evidence not found for these groups.

How to think about claims

Claims of "healing" typically cite animal work or the tiny reports above. See how to evaluate peptide claims and what the regulatory categories mean. Related: TB-500 and thymosin beta-4. For an injury, see a clinician first: talking with a health professional.